Clinical trials: Intracranial Atherosclerosis
ICAS - Intracranial Atherosclerosis
IntraCranial Angiography-derived Fraction Flow-guided Percutaneous Transluminal Angioplasty and Stenting Versus Medical Therapy (ICAS-MT)
A multicenter, open-label, blinded-endpoint, prospective, randomized controlled clinical trial with an "all comers" design.
- Trial name
- NCT05974033
- Testing
- Stenting plus medical therapy, Medical therapy alone
- Volunteers
- 536 people
- Sponsor
- Changhai Hospital
Acute Coronary Syndrome Comorbid With Cerebral Atherosclerosis
Tanhuo Decoction for Acute Coronary Syndrome With Cerebral Atherosclerosis in Elderly Patients
The goal of this clinical trial is to learn if Tanhuo decoction works to treat acute coronary syndrome combined with cerebral atherosclerosis in the elderly. It will also learn about the safety of Tanhuo decoction.
- Trial name
- NCT07445581
- Testing
- Tanhuo decoction, standard Western medicine
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Jinggang Xia, MD
Stroke, Transient Ischemic Attack
Angiogenic Markers in Cerebrovascular Disease (ANFIS)
Intracranial atherosclerosis (ICAS) is the most common cause of stroke worldwide. It carries a worse prognosis than other stroke etiologies, with an annual rate of recurrent stroke and death of 15% despite intensive medical…
- Conditions
- Stroke, Transient Ischemic Attack, Atherosclerosis, Intracranial Arterial Stenosis
- Trial name
- ANFIS (NCT04240119)
- Testing
- According to current clinical care standards
- Volunteers
- 300 people
- Sponsor
- Cedars-Sinai Medical Center
Intracranial Atherosclerosis, Stroke, Ischemic
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
One important mechanism of action of GLP1 RA is the improvement in endothelial function, which may be evaluated by the assessment of cerebral vasodilatory reserve (CVR) in patients with severe ICAD.
- Trial name
- RADIANT (NCT07282041)
- Testing
- Dulaglutide
- Where
- Singapore
- Volunteers
- 130 people
- Sponsor
- National University of Singapore
Intracranial Atherosclerosis ICAS, Hemodynamic
Digital Angiography-Derived Fractional Flow Assessment for Intracranial Stenosis
The goal of this observational study is to learn whether a digital angiography derived fractional flow reserve (DPR) measurement can improve the prediction of stroke risk in adults with symptomatic intracranial atherosclerotic…
- Conditions
- Intracranial Atherosclerosis ICAS, Hemodynamic, Stroke
- Trial name
- CASSISS-DPR (NCT07309705)
- Testing
- Standardized medical therapy targeting vascular risk factors and stroke prevention
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Xuanwu Hospital, Beijing
Intracranial Atherosclerosis
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD
Stroke is an important cause of death, disability, and memory problems in adults. The build-up of plaque in arteries inside the brain is known as "intracranial atherosclerotic disease" or "ICAD" for short, and can reduce blood…
- Trial name
- NUANCE-ICAD (NCT06714526)
- Testing
- Point-of-Care CYP2C19 Testing, ticagrelor + aspirin, clopidogrel + aspirin
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Stroke, Intracranial Atherosclerosis
Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRI
Intracranial atherosclerosis (ICAS) accounts for 10 to 40%, depending on ethnicity, of the 700,000 ischemic strokes in the United States every year.
- Trial name
- NCT03084523
- Testing
- Ferumoxytol Injectable Product
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Intracranial Atherosclerosis ICAS
Moderate Versus Intensive Lipid-lowering for Events in Asymptomatic Intracranial Stenosis
It is designed to compare two different strengths of cholesterol-lowering treatment in patients who have narrowing of blood vessels inside the brain (intracranial atherosclerosis) but do not currently have symptoms such as…
- Trial name
- MILES (NCT07791823)
- Testing
- Lipid Lowering Treatment
- Where
- South Korea
- Volunteers
- 1,626 people
- Sponsor
- Woo-Keun Seo
Intracranial Atherosclerosis, Atherosclerotic Plaque
Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)
The primary goal of the trial is to investigate whether the lipid lowering strategy using Alirocumab plus statin could cause more changes from baseline in intracranial atherosclerotic plaque and hemodynamic features during 6…
- Conditions
- Intracranial Atherosclerosis, Atherosclerotic Plaque, Stenosis
- Trial name
- EAST-aICAS (NCT06080256)
- Testing
- Alirocumab, Atorvastatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Atheroscleroses, Cerebral, Intracranial Atherosclerosis
Balloon-expandable DES for ICAS Registry Study (BDES-ICAS Registry)
To study the clinical outcomes after implantation of balloon-expandable drug-eluting stents in patients with symptomatic intracranial atherosclerotic stenosis in prevention of composite event of any stroke and death within 30…
- Conditions
- Atheroscleroses, Cerebral, Intracranial Atherosclerosis, Ischemia Stroke
- Trial name
- NCT06614972
- Testing
- Balloon-expandable drug-eluting stent
- Volunteers
- 520 people
- Sponsor
- RenJi Hospital
Cerebral Infarction, Atherosclerosis
Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
This study will recruit 480 acute stroke patients with symptomatic intracranial stenosis (M1 segment of Middle cerebral artery (MCA) or basilar artery). They will be randomly assigned into cilostazol group or clopidogrel group.
- Trial name
- TOSS-2 (NCT00130039)
- Testing
- clopidogrel, Cilostazol
- Where
- 19 sites in Hong Kong, Philippines and 2 more
- Volunteers
- 457 people
- Sponsor
- Asan Medical Center
Intracranial Atherosclerosis
Asymptomatic Intracranial Atherosclerotic Disease in Pakistanis
The incidence of stroke has increased by 100% in the last four decades in developing countries like Pakistan. Intracranial atherosclerotic disease (ICAD) is the most frequent causative subtype of ischemic stroke in the world…
- Trial name
- AICAD (NCT02072876)
- Where
- 2 sites in Pakistan
- Volunteers
- 200 people
- Sponsor
- Aga Khan University
Ischemic Stroke, Atheroscleroses, Cerebral
Morphologic Evolution and Remodeling of Intracranial Atherosclerosis: A Longitudinal Study by 3D-rotational Angiography
This study is to elucidate the morphologic evolution and remodeling of ICAD under stringent control of cardiovascular risk factors.
- Trial name
- NCT03295773
- Testing
- 3DRA
- Where
- Hong Kong
- Volunteers
- 140 people
- Sponsor
- Chinese University of Hong Kong
Intracranial Atherosclerosis
Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis
The purpose of this study is to determine the effects of the Doctormate device, a specialized blood pressure cuff used to perform remote limb ischemic conditioning, on cerebral blood flow in subjects with intracranial…
- Trial name
- PICASSO (NCT03208166)
- Testing
- Doctormate, Usual Care
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Medical University of South Carolina
Atherosclerosis
Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis
Atherosclerotic intracranial arterial stenosis (AICAS) corresponds to luminal narrowing of the major intracranial arteries. The prevalence of intracranial atherosclerotic stenosis accounts for 33% to 67% of stroke or transient…
- Trial name
- NCT02594800
- Testing
- Rosuvastatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ischemic Stroke, Atheroscleroses, Cerebral
Morphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential
The study is to attain early recognition of the unstable plaques which have an imminent embolic risk in patients with intracranial atherosclerotic disease (IAD).
- Trial name
- NCT03291652
- Testing
- DSA/3DRA
- Where
- Hong Kong
- Volunteers
- 140 people
- Sponsor
- Chinese University of Hong Kong
Stroke, Intracranial Atherosclerosis
PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and intracranial atherosclerotic disease are randomized to either drug or…
- Conditions
- Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
- Trial name
- PINNACLE (NCT03507374)
- Testing
- Alirocumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Myocardial Infarction, Ischemic Stroke
Understanding the Role of Autoimmune Disorders on the Initial Presentation of Cardiovascular Disease
Autoimmune diseases are diseases in which inappropriate immune responses that have the capability of harming host cells play an important role.
- Conditions
- Myocardial Infarction, Ischemic Stroke, Stroke, Subarachnoid Haemorrhage
- Trial name
- NCT02062021
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- University College, London
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)
The research team is conducting a randomized, double-blind, placebo-controlled, multicenter clinical study aimed at evaluating the impact of adding Tolecilimab (a PCSK9 inhibitor) to standard lipid-lowering therapy (statins ±…
- Trial name
- NCT07341958
- Testing
- Tafolecimab
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Beijing Tiantan Hospital
Abdominal Aortic Aneurysm, Coronary Heart Disease NOS
Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber)
Study of heterogeneity in associations between heart rate and the initial presentation of 12 cardiovascular diseases.
- Conditions
- Abdominal Aortic Aneurysm, Coronary Heart Disease NOS, Unheralded Coronary Death, Intracerebral Haemorrhage
- Trial name
- NCT01947361
- Where
- United Kingdom
- Volunteers
- 1,961,286 people, healthy volunteers welcome
- Sponsor
- University College, London